A new experimental drug meant to be taken just once a month could lead to “substantial weight reduction” within a year and help overcome both diabetes and obesity, a new clinical trial suggests.
Results of the trial, published on Tuesday in the journal NEJM, show that Maridebart cafraglutide, or MariTide, could reduce body weight by up to 20 per cent within a year. Even after 12 months of taking the drug, weight loss had not plateaued in the participants, indicating there was potential for further weight reduction.
